Clinical Trials Logo
  1. Home
  2. Hereditary Spastic Paraplegia
  3. NCT04912609

Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11) — 3AL-SPG11  

Hereditary Spastic Paraplegia Clinical Trial

Official title:
An Observational Study in Subjects With Spastic Paraplegia Type 11 Taking Trehalose

Clinical Trial Summary

Hereditary spastic paraparesis type 11 (SPG11) is caused by mutations in the SPG11 gene that produces spatacsin, a protein involved in lysosomal function.

Clinical Trial Description

Several experiments on subjects affected by neurodegenerative diseases with dysfunction of the autophagic-lysosomal system show that trehalose improves the pathological phenotype. This evidence indicates that trehalose could be used in patients with SPG11 to try to prevent the accumulation of glycosphingolipids at the lysosomal level and induce the genesis of new lysosomes. This study aims to record clinical data of 20 patients with SPG11 who take trehalose during 12 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04912609
Study type Observational
Source IRCCS Fondazione Stella Maris
Contact
Status Completed
Phase
Start date June 30, 2021
Completion date July 30, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06117020 - Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals Phase 1
Completed NCT05373082 - Identification of Modifying Factors in Hereditary Spastic Paraplegia
Recruiting NCT03981276 - Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
Terminated NCT02859428 - Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
Completed NCT03104088 - Studying Cognition in SPG4
Recruiting NCT05848271 - Natural History Study of Patients With HPDL Mutations
Completed NCT02604186 - Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Phase 2/Phase 3
Recruiting NCT03206190 - The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4 N/A
Completed NCT03627416 - Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy N/A
Recruiting NCT04875416 - Phenotype, Genotype and Biomarkers 2
Withdrawn NCT05411627 - A Pilot Study of Shockwave Therapy in HSP N/A
Completed NCT03961906 - Physiotherapy in Hereditary Spastic Paraplegia Phase 2
Completed NCT05767268 - Assessment of the Psychophysical State During Rehabilitation Treatment With Lokomat
Completed NCT02852278 - A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Completed NCT04180098 - Improving Gait Adaptability in Hereditary Spastic Paraplegia N/A
Completed NCT05613114 - Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia N/A
Completed NCT00023075 - Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis N/A
Recruiting NCT04712812 - Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
Recruiting NCT05354622 - Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Enrolling by invitation NCT02327845 - Phenotype, Genotype & Biomarkers in ALS and Related Disorders